Azeliragon is under clinical development by Cantex Pharmaceuticals and currently in Phase II for Refractory Brain Metastasis. According to GlobalData, Phase II drugs for Refractory Brain Metastasis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Azeliragon LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Azeliragon overview

Azeliragon is under development for the treatment of hospitalized patients with severe COVID-19, cancer-treatment related cognitive decline, chronic obstructive pulmonary disease (COPD) and steroid refractory asthma, pneumonia, metastatic pancreatic cancer, glioblastoma multiforme, gliosarcoma, triple negative breast cancer, brain metastasis and breast cancers. The drug candidate is administered through oral route and acts by targeting RAGE (receptor for advanced glycation endproducts). The drug is developed based on the TTP translational technology. It was under development for the treatment of Alzheimer’s disease (dementia with diabetes) and diabetic nephropathy.

Cantex Pharmaceuticals overview

Cantex Pharmaceuticals, formerly ParinGenix is, a clinical-stage biopharmaceutical company. It discovers and develops proprietary pharmaceuticals for the treatment of cancers and other disorders. The company’s pipeline products include HMGB1 and S100 proteins among others. Cantex Pharmaceuticals The company provides its products in therapeutic areas such as glioblastoma, brain metastasis, pancreatic cancer, breast cancer, acute kidney injury and others. The company offers its products across the US. Cantex Pharmaceuticals is headquartered in Weston, Florida, the US

For a complete picture of Azeliragon’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.